Indonesia’s Finance Minister said the safe distribution of a Covid-19 vaccine in Indonesia means that all scientific aspects must meet the recommended standards or fulfill the internationally adopted standards.
“To ensure its safety, the vaccine must pass proper clinical trials to give peace of mind to the public.”
The success and result of vaccine clinical trials as well as international safety standards determined by reputable bodies such as the WHO and the Technical Advisory Group on Immunization (ITAGI) are essential to rolling out Indonesia’s Covid-19 vaccination plans.
Sri Mulyani emphasized that Indonesia will follow international standards and that the country will not revert to any other standards.
The decision to follow international standards is to show that the Indonesian government has not accelerated Covid-19 vaccine distribution nor conducted its own mechanism of a proper coronavirus vaccine.
“By adopting the WHO and ITAGI’s standards, Indonesia will be able to start its coronavirus vaccination program even if the vaccines originate from different brands,” the Finance Minister said.
Due to the substantial amount of coronavirus vaccines needed in Indonesia — 267 million doses to be exact — the government has used this period to create a detailed plan.